Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

Objective: To assess the efficacy of capecitabineplus docetaxel(XT) versus epirubicinplus docetaxel(ET) as first-line therapy for metastatic breast cancer(MBC). Patien